

Spotlight Stock Market

12 April 2022
TICKER: DANCAN

Correction: DanCann Pharma A/S Announces the appointment of Louise Conradsen to accelerate growth as new subsidiary CEO of CannGros ApS

Correction: Due to minor confusion about whether Louise Conradsen was appointed as CEO of DanCann Pharma A/S, or the subsidiary CannGros ApS, the Company has chosen to correct its headline in its Company announcement, where the Company makes it clear that Louise Conradsen is appointed as CEO of the subsidiary, CannGros ApS. Jeppe Krog Rasmussen remains the CEO of DanCann Pharma A/S. The correction is adjusted from "DanCann Pharma A/S Announces the appointment of Louise Conradsen as new Chief Executive Officer to accelerate growth of CannGros ApS" to "DanCann Pharma A/S Announces the appointment of Louise Conradsen to accelerate growth as new subsidiary CEO in CannGros ApS".

COPENHAGEN, Denmark, 12 April 2022 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that the Company has recruited and appointed its new Chief Executive Officer ("CEO"), Louise Conradsen, for the subsidiary CannGros ApS ("CannGros") to elevate CannGros to a significantly higher commercial level strengthening the product portfolio and pipeline. Louise Conradsen will start in her new function with effect from 10th May 2022.

Louise Conradsen is a commercial management professional with more than eighteen years of experience from the pharmaceutical industry. At CannGros she will be overall responsible for operations focusing on procurement, supply chain and the whole range of securing long-lasting contracts and agreements with vendors and clients worldwide. Her strong focus on negotiations, building up client relations and the continuous optimization of processes will be important assets for the company in order to reach its strategic targets concerning growth and business development.

After DanCann Pharma's acquisition of CannGros in October 2021, Jeppe Krog Rasmussen has been CEO of both CannGros and DanCann Pharma. He will continue as Group CEO and pass the ball at CannGros to Louise Conradsen.

Christian Carlsen, Board Member DanCann Pharma A/S, comments:

The addition of Louise Conradsen as CEO must be seen as a natural continuation of the growth in CannGros and the increased focus on the subsidiary's integration in DanCann Pharma Group. We have been in dialogue with Louise for a long time on several occasions and we are confident that together we can elevate CannGros to a significantly higher commercial level strengthening the product portfolio and pipeline. Louise is very ambitious on CannGros' behalf - and we have high expectations for the upcoming collaboration.

Louise Conradsen, CEO CannGros, comments:

With more than eighteen years of relevant experience from senior level positions at Abacus Medicine A/S and Orifarm, where I was responsible for the development and implementation of processes for purchase and supply chain, I am confident, that I will be able to benefit from this knowledge and prove myself to be an important asset in the further development of CannGros in close cooperation with colleagues, suppliers, and customers. My focus will be to ensure that strategic goals for growth are met, keeping the high success rate for product delivery and time to market.

Disclaimer

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

About DanCann Pharma

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution Company based in Denmark. The Company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO
E-mail: ikr@dancann.com
Website: www.dancann.com